BioSpace News Archive

Drug Development

US FDA Backs Merck & Co., Inc. (JOBS), Schering-Plough Corporation’s (JOBS) Vytorin

January 9, 2009
·
1 min read
Drug Development

Orexigen Therapeutics, Inc. Announces First of Four Phase 3 Trials of Contrave(R) Meets Co-Primary and Key Secondary Endpoints

January 9, 2009
·
9 min read
Business

Alcon Laboratories, Inc. Names Insider Kevin Buehler as New CEO

January 9, 2009
·
4 min read
Drug Development

Catalyst Pharmaceutical Partners Reaches Enrollment Target for its U.S. Phase II Cocaine Trial

January 9, 2009
·
4 min read
Business

Galapagos NV Partners with Merck & Co., Inc., GLPG Shares Jump; Total Payments Could Exceed $233 Million

January 9, 2009
·
5 min read
Business

Alnylam Pharmaceuticals and Cubist Pharmaceuticals, Inc. Form Strategic Collaboration to Develop and Commercialize RNAi Therapeutics Targeting Respiratory Syncytial Virus (RSV) Infection; Alnylam to Get $20 Million Upfront

January 9, 2009
·
11 min read
Business

XDx, Inc. and Bristol-Myers Squibb Enter into Pharmacogenomics Collaboration

January 9, 2009
·
3 min read
FDA

FDA Advisory Committee Unanimously Recommends OVATION Pharmaceuticals (Acquired by Lundbeck in March 2009)'s Sabril(R) (vigabatrin) for the Treatment of Two Catastrophic Epilepsies

January 9, 2009
·
5 min read
Irish Domiciled Funds Exceed €1 Trillion

January 9, 2009
·
1 min read